Overview

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

Status:
Not yet recruiting

Trial end date:
2032-07-01

Target enrollment:

Participant gender:

Summary

This is an open label study of tucatinib in combination with either vinorelbine or gemcitabine and trastuzumab in patients with metastatic HER2+ breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Providence Health & Services

Collaborator:

Seagen Inc.

Treatments:

Tucatinib